SCHEMBL2011308

SCHEMBL2011308

O=C1[CH]CCC(=O)N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10909121 0.74
SCHEMBL867714 0.71
SCHEMBL11190350 0.71
SCHEMBL5163446 0.67
Succinimide SCHEMBL8361206 0.64 CRBN (1.00)
SCHEMBL290757 0.64
Succinimide SCHEMBL1326078 0.64 CRBN (1.00)
Succinimide SCHEMBL774 0.64
Succinimide SCHEMBL1466558 0.64
Succinimide SCHEMBL1600526 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024051766-A1 MOLECULAR GLUE COMPOUND BASED ON CEREBLON PROTEIN DESIGN AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-03-14 WO claimed
CN-111606883-B Sulfur-containing compound based on glutarimide skeleton and application thereof 上海科技大学 2023-05-09 CN claimed
CN-115697989-A Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use 上海睿跃生物科技有限公司 2023-02-03 CN claimed
US-20220143002-A1 SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF SHANGHAITECH UNIVERSITY (CN) 2022-05-12 US claimed
EP-3932922-A1 SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF ShanghaiTech University (CN) 2022-01-05 EP claimed
CN-111606883-A Sulfur-containing compound based on glutarimide framework and application thereof 上海科技大学 2020-09-01 CN claimed
EP-3277276-A1 METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS Calithera Biosciences Inc. (US) 2018-02-07 EP claimed
EP-3116872-A1 COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS Calithera Biosciences, Inc. (US) 2017-01-18 EP claimed
WO-2016160980-A1 METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS CALITHERA BIOSCIENCES, INC. (US) 2016-10-06 WO claimed
US-20160287564-A1 METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS CALITHERA BIOSCIENCES, INC. 2016-10-06 US claimed
US-20150258082-A1 COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS CALITHERA BIOSCIENCES, INC. 2015-09-17 US claimed
EP-1997495-B1 2-phenoxy- and 2-phenylsulfanyl-benzenesulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders AXIKIN PHARMACEUTICALS INC (US) 2013-01-02 EP claimed
EP-1608374-B9 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS ACTIMIS PHARMACEUTICALS INC (US) 2009-04-08 EP claimed
EP-2029535-A1 ISOINDOLE DERIVATIVES USEFUL FOR TREATING PAIN, GASTROINTESTINAL DISEASES AND CANCER AstraZeneca AB (SE) 2009-03-04 EP claimed
EP-1997495-A1 2-phenoxy- and 2-phenylsulfanyl-benzenesulfonamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders Actimis Pharmaceuticals, Inc., (US) 2008-12-03 EP claimed
EP-1608374-B1 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS ACTIMIS PHARMACEUTICALS INC (US) 2008-11-05 EP claimed
WO-2007139464-A1 ISOINDOLE DERIVATIVES USEFUL FOR TREATING PAIN, GASTROINTESTINAL DISEASES AND CANCER ASTRAZENECA AB (SE) 2007-12-06 WO claimed
US-20070155725-A1 2-Phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders AXIKIN PHARMACEUTICALS, INC. 2007-07-05 US claimed
EP-1608374-A1 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS Actimis Pharmaceuticals, Inc. (US) 2005-12-28 EP claimed
WO-2004084898-A1 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS ACTIMIS PHARMACEUTICALS, INC. (US) 2004-10-07 WO claimed